In an RCT comparing CamAPS FX hybrid closed-loop and sensor-augmented pump therapy (SAP) in people living with diabetes with an elevated HbA1c (7.5-10%), Tauschmann et al demonstrated that the CamAPS FX hybrid closed-loop system, in adults and children, significantly increased time in range (+10.8%, P < 0.0001) and significantly reduced HbA1c (−0.36%, P < 0.0001), time below range (−0.83%, P < .0001) and time above range (−10.3%, P < .0001) when compared to SAP, with no difference in total daily insulin dose (23). This evidence concerns the gene INS and diabetes mellitus.